Xencor (NASDAQ:XNCR) Upgraded at Wall Street Zen
by Teresa Graham · The Cerbat GemWall Street Zen upgraded shares of Xencor (NASDAQ:XNCR – Free Report) from a sell rating to a hold rating in a research note released on Saturday.
Several other research analysts have also recently issued reports on XNCR. JPMorgan Chase & Co. restated a “neutral” rating and issued a $13.00 price objective (down from $18.00) on shares of Xencor in a research note on Tuesday, March 24th. Weiss Ratings restated a “sell (d-)” rating on shares of Xencor in a research note on Friday, March 27th. Finally, Barclays raised their price objective on Xencor from $26.00 to $27.00 and gave the stock an “overweight” rating in a research note on Thursday, February 26th. Six analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $24.38.
Read Our Latest Research Report on Xencor
Xencor Trading Down 2.0%
Shares of NASDAQ:XNCR opened at $12.80 on Friday. Xencor has a 52-week low of $6.92 and a 52-week high of $18.69. The stock has a market cap of $938.75 million, a price-to-earnings ratio of -10.32 and a beta of 0.99. The company has a quick ratio of 6.25, a current ratio of 6.25 and a debt-to-equity ratio of 0.12. The business has a 50-day moving average price of $12.09 and a 200-day moving average price of $13.64.
Xencor (NASDAQ:XNCR – Get Free Report) last announced its quarterly earnings data on Wednesday, February 25th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.64) by $0.55. Xencor had a negative return on equity of 14.58% and a negative net margin of 73.20%.The firm had revenue of $28.24 million during the quarter, compared to analysts’ expectations of $29.97 million. During the same period last year, the business posted ($0.62) earnings per share. The company’s revenue for the quarter was down 46.6% compared to the same quarter last year. Equities analysts predict that Xencor will post -2.87 EPS for the current year.
Insider Buying and Selling
In related news, SVP Celia Eckert sold 3,244 shares of the firm’s stock in a transaction dated Thursday, March 5th. The stock was sold at an average price of $11.25, for a total transaction of $36,495.00. Following the sale, the senior vice president directly owned 78,685 shares of the company’s stock, valued at $885,206.25. This trade represents a 3.96% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP John R. Desjarlais sold 2,502 shares of the firm’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $11.02, for a total value of $27,572.04. Following the sale, the vice president directly owned 263,831 shares in the company, valued at approximately $2,907,417.62. This trade represents a 0.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 44,020 shares of company stock valued at $499,817 over the last ninety days. Company insiders own 5.23% of the company’s stock.
Institutional Trading of Xencor
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Hantz Financial Services Inc. grew its holdings in Xencor by 209.1% during the third quarter. Hantz Financial Services Inc. now owns 3,187 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 2,156 shares during the period. GAMMA Investing LLC grew its holdings in Xencor by 77.1% during the third quarter. GAMMA Investing LLC now owns 3,328 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 1,449 shares during the period. Farther Finance Advisors LLC acquired a new stake in Xencor during the third quarter worth about $44,000. Tower Research Capital LLC TRC grew its holdings in Xencor by 118.4% during the second quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company’s stock worth $44,000 after acquiring an additional 3,018 shares during the period. Finally, Federated Hermes Inc. grew its holdings in Xencor by 114.3% during the third quarter. Federated Hermes Inc. now owns 3,947 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 2,105 shares during the period.
About Xencor
Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor’s research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.
The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.